Advanced Malignant Solid Tumor Clinical Trials

33 recruitingLast updated: June 17, 2026

There are 33 actively recruiting advanced malignant solid tumor clinical trials across 8 countries. Studies span Phase 1, Phase 2, Not Applicable, Early Phase 1. Top locations include Shanghai, Shanghai Municipality, China, Beijing, China, Guangzhou, Guangdong, China. Updated daily from ClinicalTrials.gov.


Advanced Malignant Solid Tumor Trials at a Glance

33 actively recruiting trials for advanced malignant solid tumor are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 1 with 26 trials, with the heaviest enrollment activity in Shanghai, Beijing, and Guangzhou. Lead sponsors running advanced malignant solid tumor studies include Minghui Pharmaceutical (Hangzhou) Ltd, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, and Shanghai Junshi Bioscience Co., Ltd..

Browse advanced malignant solid tumor trials by phase

Treatments under study

About Advanced Malignant Solid Tumor Clinical Trials

Looking for clinical trials for Advanced Malignant Solid Tumor? There are currently 16 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced Malignant Solid Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced Malignant Solid Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 33 trials

Recruiting
Phase 1

CT-95 in Advanced Cancers Associated With Mesothelin Expression

Colorectal, CancerMesothelin-Expressing TumorsEpithelial Ovarian Cancer+8 more
Context Therapeutics Inc.70 enrolled9 locationsNCT06756035
Recruiting
Phase 2

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

Advanced malignant solid tumors
Shanghai Junshi Bioscience Co., Ltd.410 enrolled1 locationNCT07480733
Recruiting
Phase 1Phase 2

A Study of MHB009C in Patients With Advanced Solid Tumors

Advanced Malignant Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd200 enrolled1 locationNCT07326488
Recruiting
Phase 1Phase 2

A Study of MHB048C in Patients With Advanced Solid Tumors

Advanced Malignant Solid TumormCRPC (Metastatic Castration-resistant Prostate Cancer)
Minghui Pharmaceutical (Hangzhou) Ltd200 enrolled1 locationNCT07192120
Recruiting
Phase 1Phase 2

A Study of MHB042C in Patients With Advanced Solid Tumors

Advanced Malignant Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd200 enrolled1 locationNCT07192107
Recruiting
Phase 1

Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors

Advanced malignant solid tumorsMetastatic Malignant Solid Tumors
Genmab45 enrolled5 locationsNCT06573294
Recruiting
Phase 1

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors

Advanced Malignant Solid Tumor
Shanghai Virogin Biotech Co., Ltd.30 enrolled1 locationNCT07262164
Recruiting
Not Applicable

Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors

HER2-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.30 enrolled1 locationNCT06658951
Recruiting
Phase 1Phase 2

A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors

Advanced malignant solid tumors
FindCure Biosciences (ZhongShan) Co., Ltd.33 enrolled1 locationNCT06499350
Recruiting
Phase 1

A First in Human Study of PLT012 in Participants With Solid Tumor Cancers

Solid Tumor CancerAdvanced Malignant Solid Tumor
Pilatus Biosciences Inc36 enrolled2 locationsNCT07337525
Recruiting
Phase 1Phase 2

An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors

Advanced Malignant Solid Tumor
Repertoire Immune Medicines150 enrolled1 locationNCT07293754
Recruiting
Phase 1

A Study of CSCJC3456 in Patients With Advanced Malignant Tumors

Advanced malignant solid tumors
Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.102 enrolled2 locationsNCT06717750
Recruiting
Phase 1

A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Advanced Malignant Solid TumorHepatic Impairment
Epizyme, Inc.24 enrolled18 locationsNCT04241835
Recruiting
Phase 1

JSKN022 in Subjects With Advanced Malignant Solid Tumors

Advanced malignant solid tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd225 enrolled1 locationNCT07292402
Recruiting
Early Phase 1

A Clinical Study on Evaluating Intravenous Administration of IDOV-SAFE

Advanced Malignant Solid Tumor of Digestive System
Peking University89 enrolled1 locationNCT06380309
Recruiting
Phase 2

A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors

Advanced Breast CancerAdvanced Malignant Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd210 enrolled1 locationNCT07130383
Recruiting
Phase 1Phase 2

A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd116 enrolled1 locationNCT07126665
Recruiting
Phase 1Phase 2

Phase I/II Study of SCTB39-1 in Advanced Solid Tumours

Advanced Malignant Solid Tumor
Sinocelltech Ltd.110 enrolled1 locationNCT07050641
Recruiting
Phase 1

A Study of MHB118C Injection in Patients With Advanced Solid Tumors

Advanced Malignant Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd200 enrolled1 locationNCT07045454
Recruiting
Not Applicable

Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors

Mesothelin-positive Advanced Malignant Solid Tumors
Zhejiang University24 enrolled1 locationNCT07010523